Zevra Therapeutics (ZVRA) announced that all three leading proxy advisory firms, Institutional Shareholder Services, Glass Lewis & Co, and Egan-Jones Proxy Services have recommended that stockholders vote “FOR” Wendy Dixon, Ph.D. and Tamara Favorito and “WITHHOLD” on dissident nominees Travis Mickle and Arthur Regan on the WHITE proxy card at the upcoming 2025 Annual Meeting of Stockholders, scheduled to be held on May 29, 2025.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics Shines in Earnings Call with MIPLYFFA Success
- Zevra Therapeutics: Strong Financial Performance and Strategic Initiatives Drive Buy Rating
- Zevra Therapeutics: Strong Sales and Strategic Initiatives Drive Buy Rating
- Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance
- Zevra Therapeutics price target raised to $19 from $18 at Citizens JMP